Cargando…
Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response?
OBJECTIVE: We compared therapeutic response of Varlitinib + Capecitabine (VC) versus Lapatinib + Capecitabine (LC) in patients with human epidermal growth factor receptor 2‐positive metastatic breast cancer after trastuzumab therapy by assessing changes in target lesion (TL) diameter and volume per...
Autores principales: | Beaumont, Hubert, Faye, Nathalie, Iannessi, Antoine, Chamorey, Emmanuel, Klifa, Catherine, Hsieh, Chih‐Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939226/ https://www.ncbi.nlm.nih.gov/pubmed/36098367 http://dx.doi.org/10.1002/cam4.5236 |
Ejemplares similares
-
Breaking down the RECIST 1.1 double read variability in lung trials: What do baseline assessments tell us?
por: Iannessi, Antoine, et al.
Publicado: (2023) -
Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?
por: Beaumont, Hubert, et al.
Publicado: (2023) -
Letter to the editor: “Not all biases are bad: equitable and inequitable biases in machine learning and radiology”
por: Iannessi, Antoine, et al.
Publicado: (2021) -
How reliable are ADC measurements? A phantom and clinical study of cervical lymph nodes
por: Moreau, Bastien, et al.
Publicado: (2018) -
RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
por: Iannessi, Antoine, et al.
Publicado: (2021)